ALK Clinical Trials

66 recruitingLast updated: June 18, 2026

There are 66 actively recruiting alk clinical trials across 32 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3. Top locations include Boston, Massachusetts, United States, Chicago, Illinois, United States, Aurora, Colorado, United States. Updated daily from ClinicalTrials.gov.


ALK Trials at a Glance

66 actively recruiting trials for alk are listed on ClinicalTrialsFinder across 6 cities in 32 countries. The largest study group is Not Applicable with 21 trials, with the heaviest enrollment activity in Boston, Chicago, and Aurora. Lead sponsors running alk studies include Northwestern University, Hunan Province Tumor Hospital, and Pfizer.

Browse alk trials by phase

Treatments under study

About ALK Clinical Trials

Looking for clinical trials for ALK? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new ALK trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about ALK clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 66 trials

Recruiting
Phase 1Phase 2

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

ALK-Positive Lung CancerALK-positive Non-small Cell Lung CancerALK-positive NSCLC
TRIANA Biomedicines, Inc.160 enrolled9 locationsNCT07491497
Recruiting
Phase 1

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)Anaplastic Lymphoma Kinase (ALK) Positive
Astellas Pharma Global Development, Inc.40 enrolled15 locationsNCT07140016
Recruiting

Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib

Lung AdenocarcinomaDepressionCognitive Dysfunction+3 more
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo24 enrolled1 locationNCT07633626
Recruiting

Study of Alkaptonuria

Alkaptonuria
National Human Genome Research Institute (NHGRI)300 enrolled1 locationNCT00005909
Recruiting
Phase 1Phase 2

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

ALK Fusion-positive Solid or CNS Tumors
Hoffmann-La Roche42 enrolled33 locationsNCT04774718
Recruiting
Not Applicable

Word Learning in Bilingual Typical and Late Talking Children: The Role of Meaning and Input

BilingualismVocabulary AcquisitionLate Talkers+1 more
Boston University Charles River Campus80 enrolled1 locationNCT07600242
Recruiting

A Registry for People With T-cell Lymphoma

T-cell LymphomaNK-Cell LymphomaT-cell Prolymphocytic Leukemia+27 more
Memorial Sloan Kettering Cancer Center1,000 enrolled26 locationsNCT05978141
Recruiting
Phase 2

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

Anaplastic Large Cell Lymphoma, ALK-Positive
New York Medical College20 enrolled1 locationNCT07013565
Recruiting
Phase 3

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedAnaplastic Large Cell Lymphoma, ALK-negativeFollicular Helper T-Cell Lymphoma+1 more
Eastern Cooperative Oncology Group294 enrolled158 locationsNCT06724237
Recruiting
Not Applicable

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

ALK+ Non-Small-Cell Lung Carcinoma
Pfizer90 enrolled31 locationsNCT06487078
Recruiting
Not Applicable

Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC

Non-small Cell Lung CancerALK Gene Rearrangement Positive
Groupe Francais De Pneumo-Cancerologie100 enrolled46 locationsNCT05122806
Recruiting
Not Applicable

Body Weight-Supported and Virtual Reality Gait Training in Stroke Patients

StrokeBalanceWalking Impairment+1 more
Gaziler Physical Medicine and Rehabilitation Education and Research Hospital30 enrolled1 locationNCT07550270
Recruiting
Not Applicable

ENhancing Exercise With LIGHT to Improve Functioning in PAD

AgingWalking, DifficultyPeripheral Artery Disease+1 more
Northwestern University32 enrolled1 locationNCT06399900
Recruiting
Phase 2

Fisetin to Reduce Senescence and Mobility Impairment in PAD

ClaudicationPeripheral Arterial DiseaseAging+2 more
Northwestern University34 enrolled1 locationNCT06399809
Recruiting
Phase 3

SMART Exercise for PAD

Peripheral Arterial DiseaseAgingWalking, Difficulty+1 more
Northwestern University210 enrolled3 locationsNCT06032065
Recruiting
Not Applicable

A Motor Learning Intervention to Target Walking Performance in Ambulant Children With Cerebral Palsy

Cerebral PalsyWalking, DifficultyHemiplegic cerebral palsy+1 more
Royal College of Surgeons, Ireland14 enrolled1 locationNCT06454656
Recruiting
Phase 1Phase 2

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Colorectal, CancerHepatocellular CarcinomaMelanoma+15 more
7 Hills Pharma, LLC126 enrolled5 locationsNCT06362369
Recruiting
Phase 1

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Hodgkin LymphomaNon-Hodgkin LymphomaPeripheral T Cell Lymphoma+4 more
Baylor College of Medicine90 enrolled2 locationsNCT06176690
Recruiting
Phase 1Phase 2

Alectinib Pharmacokinetic in Patients With NSCLC

ALK Gene MutationNon-small Cell Lung Cancer Stage IIIB
Instituto Nacional de Cancerologia de Mexico45 enrolled1 locationNCT05713006
Recruiting
Not Applicable

Effects of Treadmill-Based Gait Training in Patients With Stroke

EnduranceGaitGait Analysis+3 more
University of Salamanca24 enrolled1 locationNCT07127861